M. Holland

Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long‐acting glucagon‐like peptide‐1 mimetic, in healthy subjects

M. Bush, M. Stewart, E. D. De Boever, 2009, Diabetes, obesity & metabolism.

Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes.

M. Bush, M. Stewart, E. D. De Boever, 2008, The Journal of clinical endocrinology and metabolism.

Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Albiglutide, a Long-Acting GLP- 1 Mimetic, in Patients With Type 2 Diabetes

M. Bush, M. Stewart, R. Dobbins, 2008 .

Assessing the Impact of Losmapimod on Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis

B. Rovin, R. Willette, D. Gipson, 2020, Kidney international reports.

Autoantibodies to Variable Heavy (VH) Chain Ig Sequences in Humans Impact the Safety and Clinical Pharmacology of a VH Domain Antibody Antagonist of TNF-α Receptor 1

D. Lipson, A. Serone, A. Bayliffe, 2013, Journal of Clinical Immunology.

A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus

Y. Seino, N. Inagaki, H. Nakajima, 2014, Current medical research and opinion.

Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium

E. Havrdová, X. Mariette, S. Lacroix-Desmazes, 2015, Clinical and experimental immunology.

Autoantibodies to Variable Heavy (VH) Chain Ig Sequences in Humans Impact the Safety and Clinical Pharmacology of a VH Domain Antibody Antagonist of TNF-α Receptor 1

A. Serone, A. Bayliffe, M. Holland, 2013, Journal of Clinical Immunology.